Doxycycline (200mg/day) or Placebo
475
Phase 3 small_molecule completed
Quick answer
Doxycycline (200mg/day) or Placebo for Persian Gulf Syndrome is a Phase 3 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Persian Gulf Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed